Several new cohorts were designed around anti-MDA5 antibodies to explore the distribution and impact of anti-MDA5 antibodies in patients with CADM and CDM and to clarify differences in clinical, treatment-related, and prognostic features between patients with CADM and those with CDM. This evidence concerns the gene IFIH1 and clinically amyopathic dermatomyositis.